MetaCap

Adlai Nortye Group (ANL) vs Crescent Biopharma (CBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Adlai Nortye Group (ANL) has outperformed Crescent Biopharma (CBIO) over the past year, gaining 533.3% versus a loss of 0.5%. Adlai Nortye Group is the larger company by market cap ($550.6 million vs $543.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANL+533.33%CBIO-0.46%
+1188%+547%-93%
Nov 21, 20251 yearNov 20, 2026
ANL-43.00%CBIO-91.33%
+130%+13%-105%
Sep 25, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANL versus CBIO key metrics
MetricANLCBIO
Share price$8.55$13.00
Market cap$550.60M$543.21M
1-day change-5.63%+0.70%
YTD return+502.11%+9.61%
1-year return+533.33%-0.46%
5-year return—-92.74%
EPS (TTM)$-0.66$-7.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$10.84M
Net income (latest FY)$-51.87M$-153.94M
Operating margin—-1407.52%
Net margin—-1419.61%
52-week high$17.25$27.41
52-week low$0.879$8.72
Distance from 52-week high-50.43%-52.57%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+245.03%+148.69%
Average volume244.74K361.17K
Shares outstanding58.73M38.90M
Employees10980
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANL has outperformed CBIO by 533.8 percentage points over the past year.

About Adlai Nortye Group

ANL stock →

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.

Health Care · Biotechnology: Pharmaceutical Preparations · 109 employees

About Crescent Biopharma

CBIO stock →

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.

Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees

ANL vs CBIO FAQ

Which is bigger, Adlai Nortye Group or Crescent Biopharma?

Adlai Nortye Group (ANL) is larger, with a market capitalization of $550.60M compared with $543.21M for Crescent Biopharma (CBIO).

Which stock has performed better over the past year, ANL or CBIO?

ANL returned +533.33% over the past 12 months, compared with -0.46% for CBIO (price return, excluding dividends). Past performance does not predict future results.

Are Adlai Nortye Group and Crescent Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons